Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517540 · ClinicalTrials.gov registry record · Phase 2
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
NCT03517540 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 193 participants.
The verdict
NCT03517540, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Interventions
- DRUG Tropifexor (LJN452)
- DRUG Cenicriviroc (CVC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03517540
The ClinicalTrials.gov registry entry for NCT03517540 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tropifexor (LJN452) is the first listed.
NCT03517540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03517540 about?
NCT03517540 is a clinical study titled "Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis". The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
What is the current status of trial NCT03517540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2018-09-11. Estimated completion is 2020-10-15.
What interventions are being tested in trial NCT03517540?
The interventions under investigation include: Tropifexor (LJN452) (DRUG), Cenicriviroc (CVC) (DRUG).
Who is sponsoring clinical trial NCT03517540?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.